

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	7728183
<b>Application Number:</b>	09993647
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	1010
<b>Title of Invention:</b>	omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
<b>First Named Inventor/Applicant Name:</b>	Bernd Riedl
<b>Customer Number:</b>	23599
<b>Filer:</b>	Richard J. Traverso/Janet Jacobs
<b>Filer Authorized By:</b>	Richard J. Traverso
<b>Attorney Docket Number:</b>	BAYER 18A
<b>Receipt Date:</b>	02-JUN-2010
<b>Filing Date:</b>	27-NOV-2001
<b>Time Stamp:</b>	13:11:46
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	T-F1-CL38688-1.pdf	185874 <small>aca0e0ee344326fdd59331473366185d25d f852c</small>	no	32

### Warnings:

### Information:

2	NPL Documents	T-I1-DE-487014-C1-1.pdf	39807	no	2
			4e7002ca227231bf34b5f669c6b8d09e7da62ea3		
<b>Warnings:</b>					
<b>Information:</b>					
3	NPL Documents	T-I3-DE-523437-C1-1.pdf	46472	no	3
			2369e8851eaf42cece0c316c6735e082e3c9bf5		
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	T-P3a-Arzneimitteltherapie-1.pdf	272861	no	9
			554f5cdcc495d8a7608afa4baf6ef57d6fa61622		
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	T-P23-Foussard-Blanpin-ComparitivePharmacodynamic study-EN-1.pdf	248404	no	12
			326709e7d43b29630f861eea8ba6a2d0e8e910ee		
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	T-P49a-ClausAuchEin-1.pdf	32834	no	3
			ffb05fcedde7bc2f8f0e84f6a33ba28b6961f8a		
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	T-P59a-DehtlingGrosseOnkologiePipeline-1.pdf	82874	no	3
			7f8d10fb69c23400c457988e9b5fbd589789930		
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	T-P64c-DrevsMedizinischeWelt-1.pdf	40582	no	3
			05a7d23f4dc1bac0a243894c60c6ed2b9bfe0881		
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	T-P132b-JungmayrAktuellerStandKrebstherapie-1.pdf	79582	no	5
			57366b2b8ca599debc65409d6b885ecd4dec94f1		
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	T-P139-KempterSynthese-1.pdf	201309	no	19
			84da1fb0f70e968b1a0a6a1eb5643561e08235e8		
<b>Warnings:</b>					
<b>Information:</b>					

11	NPL Documents	T-P148-Kuefer0133WO- Translationalresearch-1.pdf	189125 ba4fdd77cea21a8c106ffd4c0e9f16382c592380	no	9
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	T-P151-KuriketetalKyphketal- Russian-withdiag-1.pdf	133177 c99db781f2a75e4b8abe7ea82ffb0ffbc88f4869	no	4
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	T-P172a- MedingeretalHemmung-1.pdf	42641 dbd635a8a1efb602ff9837ed9761ddad3c7d8c32	no	3
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	T-P172b- MedReportDeutschland-1.pdf	27964 83703fd008c5e5d037b6799785a905f9e5ccf495	no	2
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	T-P174-Michalies- JLACBF1913-1.pdf	23687 6d4d80139f0fee7247da7f718d1b56faefa82dce	no	2
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	T-P210b-PetersHDSorafenib-1. pdf	62021 d640c4d7e8ebaa5f32737686ce25267281dabfc	no	8
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	T-P266a- StrumbergetalSorafenib-1.pdf	53610 c96059b85140e00a5f274bbed039a956ea4cafc	no	4
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	T-P294a- WissenschaftKrebsformel-1.pdf	66011 e9d24590e87e0911ba6942aff895b494297544fc	no	8
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			1828835		

**This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.**

**New Applications Under 35 U.S.C. 111**

**If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.**

**National Stage of an International Application under 35 U.S.C. 371**

**If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.**

**New International Application Filed with the USPTO as a Receiving Office**

**If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.**